← Eichor
Study identifier: NCT03547856 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"

Condition: Hypertension · Blood Pressure · Cardiovascular Diseases  ·  Sponsor: Yan Li

PhaseN/A
Planned participants10000
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

24 hour ambulatory blood pressure (ABP) monitoring should be the first choice for diagnosis and treatment of hypertension according to European Societyof Hypertension (ESH) and the European Society of Cardiology (ESC) guideline on ambulatory blood pressure monitoring. Finally, we should promote the clinical application of 24 hour ambulatory blood pressure monitoring to greatly improve the management level of hypertension in China and effectively reduce the risk caused by hypertension in the population. Information of hypertensive patients with ambulatory blood pressure monitoring was prospectively registered nationwide,and then to investigate whether there was difference in cardiovascular prognosis according to the control of ABP.

This description comes directly from the study's public registry record.

Talk to the study team

Yan Li, Professor  ·  021-64370045  ·  liyanshcn@yahoo.com

Always discuss trial participation with your own doctor first.

Locations (1)

Ruijin HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03547856